CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES



Volume: 03 Issue: 02 | Mar-Apr 2022 ISSN: 2660-4159

http://cajmns.centralasianstudies.org

Literature Review of Cardiovascular Pathology in Coronavirus Infection

1. Yusupova Mamlakat

Received 25th Feb 2022,
Accepted 10th Mar 2022,
Online 20th Apr 2022

[1] Fergana Medical Institute of Public Health Department of Internal Medicine №1

Abstract: In the context of globalization, a new type of coronavirus infection has led the entire healthcare system of all countries to a high alert mode, which made it possible to comprehensively study this disease and its complications. This article summarizes changes in the cardiovascular system based on the publications of European and Chinese scientists.

Key words: Coronavirus infection, COVID-19, cardiovascular system, myocarditis, arrhythmia, cardiogenic syndrome, stroke.

Introduction

SARS-CoV-2 infection has serious cardiovascular consequences, including myocardial injury, myocarditis, acute coronary syndrome, pulmonary embolism, stroke, arrhythmias, heart failure, and cardiogenic shock.

Cardiac manifestations of COVID-19 may be associated with adrenergic effects, systemic inflammatory response, macrophage activation syndrome, direct viral infection of myocardial and endothelial cells, hypoxia due to respiratory failure, electrolyte imbalance, fluid overload, and side effects of some COVID-19 medications.

The effect of a previous infection caused by SARS-CoV-2 on long-term consequences in patients with cardiovascular pathology remains not fully understood. At the same time, an equally important issue is the risk of occurrence, the course of diseases of the cardiovascular system and the choice of therapy after suffering COVID-19.

Main part

Myocardial damage. Myocardial injury is defined by elevated troponin levels and can be caused by both ischemic and non-ischemic factors. One of the possible mechanisms of acute myocardial injury caused by SARS-CoV-2 infection may be its affinity for ACE2, which is widely expressed in the heart, which leads to direct damage to it [1,2]. Other hypothesized factors are: cytokine storm caused by dysregulation of T helper types 1 and 2, hyperreactivity of the sympathetic nervous system, anemia, and hypoxic damage to myocardial cells caused by respiratory dysfunction (type 2 myocardial infarction) [3]. According to studies from China, myocardial injury occurs in 7-20% of hospitalized patients with COVID-19 [4]. SARS-CoV-2-associated myocardial injury occurred in 5 of 41 COVID-19 patients (12.2%) in Wuhan, as identified by elevated levels of highly sensitive troponin I (>28

pg/mL) [5]. In a small meta-analysis (4 studies, 341 patients), troponin I levels were significantly higher in patients with severe symptoms associated with COVID-19 [6] compared with moderate patients. Myocardial injury, present in 19.7% of patients with COVID-19, was associated with higher levels of inflammatory cytokines, severe lung injury, and a high need for noninvasive and invasive ventilation. These patients were more likely to develop ARDS, acute kidney injury, impaired coagulation hemostasis, and were associated with a higher risk of death. [7]

Myocarditis and pericarditis In a series of reports of 68 deaths in a cohort of 150 patients with COVID-19, in 33% of cases, myocardial inflammation could play a role in the cause of death. Patients with COVID-19 with non-acute myocardial injury may experience either transient viremia or migration of infected macrophages from the lungs. The available data do not exclude the classic manifestation of myocarditis (i.e., direct infection of myocardial cells with a virus), although there is an assumption that myocardial involvement in COVID-19 is rather caused by a cytokine storm [8]. Patients with COVID-19 have an aberrant T cell and monocyte response leading to a systemic hyperinflammatoryresponse characterized by increased production of pro- inflammatory cytokines and chemokines (tumor necrosis factor, IL-2, IL-6, IL-7, CCL2, etc.) . Which leads to myocardial damage through infiltration of mononuclear cells into cardiomyocytesof patients with fulminant myocarditis and a high viral load of SARS-CoV-2. Pericarditis is described in the literature by isolated cases, as an acute manifestation of COVID-19, and as long-term complications after SARS-CoV-2 infection [9, 10].

Acute coronary syndrome. COVID-19 increases the risk of coronary plaque rupture as a result of an intense inflammatory response [11]. As previously reported by Kwongetal . patients with acute respiratory infections have an increased risk of subsequent development of acute myocardial infarction both after influenza and after other viral diseases, including COVID-19 [12]. The actual prevalence of ACS during COVID-19 infection is unknown given the gaps in identification of SARS-CoV-2 observed in many countries during the early stages of the pandemic, especially in the absence of typical symptoms suggestive of COVID-19 infection [13].

In 28 Italian Patients with ST Elevation Myocardial Infarction (STEMI) and COVID-19 Stefaninietal . reported that ST segment elevation is one of the most common cardiovascular complications of COVID-19 (85.7%) [14]. It should be noted that angiography demonstrated the absence of coronary artery obstruction (CHD) in 39.3% of cases. Similar data was presented by researchers from the United States Bangaloreetal . who found that one third of patients with ACS clinic had no obstruction of the coronary arteries according to angiography. In these patients with STEMI , the hospital mortality rate was 72% [15]. In addition to type 2 myocardial infarction, "myocarditis" and stress cardiomyopathy , microvascular thrombosis has also been proposed as a mechanism underlying certain cases mimicking manifestations, ST elevation without obstructive CAD, given the endothelial dysfunction and hypercoagulable state associated with COVID-19 [16].

Cardiac arrhythmias In 138 hospitalized patients with COVID-19, arrhythmias were the leading complication (19.6%) and were more common in patients requiring ICU transfer (44.4% vs 6.9%). Guoetal . showed that in 187 patients with COVID- 19, malignant ventricular arrhythmias occurred twice as often in the presence of elevated troponin levels (11.5% vs. 5.2%). Ventricular arrhythmias may also represent the first clinical manifestation of SARS-CoV-2 infection. In 136 patients with COVID-19 who underwent cardiac arrest in the hospital, Shaoetal . found that the most common initial rhythm was asystole in 89.7% of cases [17]. Pulseless electrical activity was detected in 4.4%, while a rhythm requiring pacing was detected in only 5.9% of patients. In 4 provinces of Italy Baldietal . reported a 58% increase in out-of-hospital cardiac arrest in the 40 days of the COVID-19 outbreak compared to the same period in 2019 [18].

Under the conditions of COVID-19, arrhythmias can be caused by the following mechanisms: direct viral damage to myocardial cells and/or conduction system; worsening of pre-existing heart disease or conduction disorders; electrolytic disturbances; adrenergic stress leading to electrical instability; and ACS with ongoing ischemia [19]. The high inflammatory activity characteristic of COVID-19 is another potentially important proarrhythmicfactor. Inflammation is a new risk factor for long QT syndrome and torsadesdepointes , primarily due to the direct effect of cytokines, in particular, IL-1, IL-6 and TNF-α on the myocardium, disrupting the functioning of cardiomyocyte channels (K + and Ca ++) [20].

Heart failure and cardiogenic shock. Concomitant heart failure has been observed in 23–49% of patients infected with COVID-19 [21,22]. It was associated with a worse prognosis, as it occurred almost 5 times more often in patients who did not survive hospitalization (51.9% vs. 11.7%) [23]. As with troponin , elevated levels of B-type natriuretic peptides (BNP/NT- proBNP) are associated with poor outcomes in patients with ARDS [24]. In the setting of COVID-19, heart failure may be associated with either an exacerbation of underlying cardiovascular disease or a new onset of cardiomyopathy (especially myocarditis or stress cardiomyopathy). Isolated right ventricular failure can occur with pulmonary hypertension associated with severe ARDS or pulmonary embolism [25].

Moreover, in elderly people with cardiovascular disease, left ventricular hypertrophy and diastolic dysfunction are often observed. Thus, these patients may be prone to developing pulmonary edema if they are given copious intravenous fluids to maintain blood pressure or as a means of parenteral drug administration [26].

Venous thromboembolism and pulmonary embolism. Patients with COVID-19 have an increased risk of venous thromboembolism (VTE). In addition to prolonged immobilization, endothelial injury and vascular inflammation contribute to the development of a hypercoagulable state . In a multicentre Chinese study, an increase in D- dimer levels (>1000 μg/L) was an independent predictor of hospital death [27]. In a study of 184 patients with severe COVID-19 from 3 centers in the Netherlands, 31% of patients developed VTE despite pharmacological prophylaxis [28]. Poissyetal . reported an incidence of pulmonary embolism (PE) of 20.4% (95% CI, 13.1–28.7%) in patients with severe or very severe COVID-19 [28]. In 90.1% of cases, PE occurred in patients already receiving prophylactic antithrombotic treatment. The incidence of thromboembolism in this cohort was significantly higher than that observed before the pandemic in patients with various conditions of similar severity [29].

Stroke. Ischemic stroke has been recognized as a complication of severe forms of COVID-19, which is thought to be associated with a highly prothromboticstate and severe infection-induced endothelial dysfunction [30]. Beyroutietal . reported a series of cases of stroke in 6 patients with COVID-19; large vessel occlusion with markedly elevated D- dimer levels (≥1000 μg/l) was observed in all patients. Three patients had multifocal stroke; 2 had concurrent VTE; and in 2 cases, ischemic stroke occurred during anticoagulant therapy [31]. Similarly, Oxleyetal . reported 5 young patients with COVID-19 (aged 33 to 49 years) who had suffered large vessel ischemic stroke [32].

Conclusion : With coronavirus , cardiovascular complications we show an average of 20 to 49 percent, depending on the type of pathology . The most common among which are inflammatory diseases of the myocardium and a complication of concomitant pathology from the cardiovascular system. This high trend obliges medical staff to more closely examine the cardiovascular system in patients with coronavirus infection. We believe that a screening study of biochemical markers of the cardiovascular system in patients with coronavirus infection can help to reduce mortality among patients and speed up the recovery process

Listliterature :

1. Zheng YY, Ma YT, Zhang JY, XieX. COVID-19 and the cardiovascular system. Nat Rev Cardiol . 2020;17: 259–260.
2. Wu Z., McGoogan JM Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020; 323:1239 -1242.
3. Zheng YY, Ma YT, Zhang JY, XieX. COVID-19 and the cardiovascular system. Nat Rev Cardiol . 2020;17: 259–260.
4. DrigginE., MadhavanMV, BikdeliB. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am CallCardiol . 2020; 75:2352 -2371.
5. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395: 497–506.
6. Tam CCF, Cheung K.-S., Lam S. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020; 13:e 006631.
7. Li Q., Guan X., Wu P. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N EnglJ Med. 2020;382: 1199–1207.
8. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, TondoC. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol . 2020;31: 1003–1008.
9. Shao F., Xu S., Ma X. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. Resuscitation. 2020;151: 18–23.
10. BaldiE., SechiGM, Mare C. Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy. N EnglJ Med. 2020
11. LazzeriniPE, BoutjdirM., CapecchiPL COVID-19, arrhythmic risk and inflammation: mind the gap! [epubahead of print] Circulation. 2020 doi : 10.1161/CIRCULATIONAHA.120.047293.
12. Sapp JL, AlqarawiW., MacIntyreCJ Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: a statement from the Canadian Heart Rhythm Society. Can J Cardiol . 2020;36: 948–951.
13. Zhou F., Yu T., Du R. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395: 1054-1062.
14. StefaniniGG, MontorfanoM., TrabattoniD. ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. circulation. 2020;141:2113 -2116.
15. Bangalore S., Sharma A., SlotwinerA. ST-segment elevation in patients with Covid-19: a case series. N EnglJ Med. 2020
16. Chen T., Wu D., Chen H. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: a retrospective study. BMJ. 2020;26 368:m1091.
17. MacLarenG., Fisher D., Brodie D. Preparing for the most critically ill patients with COVID-18. JAMA. 2020;323:1245.
18. Zeng Y., CaiZ., XianyuY., Yang BX, Song T., Yan Q. Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series. Critcare. 2020;24:148 .

19. KlokFA, KruipMJHA, van der Meer NJM Incidence of thrombotic complications in critically ill ICU patients with COVID-19. ThrombRes. 2020;191: 145–147.

20. MehraMR, RuschitzkaF. COVID-19 illness and heart failure. JACC Heart Fail. 2020;8: 512–514.

21. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thrombhaemost. 2020;18: 844–847.

22. KlokFA, KruipMJHA, van der Meer NJM Incidence of thrombotic complications in critically ill ICU patients with COVID-19. ThrombRes. 2020; 191: 145–147.

23. PoissyJ., GoutayJ., Caplan M. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence [epubahead of print] Circulation. 2020 doi: 10.1161/CIRCULATIONAHA.120.047430.

24. BikdeliB., MadhavanMV, Jimenez D. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Call Cardiol . 2020;75: 2950–2973.

25. Mao L., Jin H., Wang M. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77: 683–690.

26. BeyroutiR., Adams ME, Benjamin L. Characteristics of is chaemic stroke associated with COVID-19 [epubahead of print] J Neurol Neurosurgical Psychiatry. 2020 doi : 10.1136/jnnp-2020-323586.

27. Oxley TJ, MoccoJ., MajidiS. Large-vessel stroke as a presenting feature of Covid-19 in the young. N EnglJ Med. 2020; 382:e 60.

28. Rodríguez-Leor O., Cid- ÁlvarezB., Ojeda S. Impactode la pandemiade COVID-19 sobrela actividad assistenc ialencardiology in terventionistaen España . REC IntervCardiol . 2020;2: 82–89.

29. MoroniF., GramegnaM., AjelloS. Collateral damage: medical care avoidance behavior among patients with myocardial infarction during the COVID-19 pandemic [Epubahead of print] JACC Case Reports. 2020 doi : 10.1016/j.jaccas.2020.04.010.

30. Kim AHJ, Sparks JA, LiewJW A Rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxyl chloroquine for COVID-19. Ann Intern Med. 2020; 172: 819–821.

31. Sanders JM, MonogueML, JodlowskiTZ, CutrellJB Pharmacologic treatments for coronavirus disease 2019 (COVID-19) [Epubahead of print] JAMA. 2020 doi : 10.1001/jama.2020.6019.